ASCO Annual Meeting

Anthony Conley, MD, discussed findings from a phase 1/2 study investigating the oncolytic virus AdAPT-001 in patients with solid tumors presented at ASCO 2024.

Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.

Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

Aditya Bardia, MD, MPH, discusses results of a biomarker analysis of the TROPiCS-02 study of sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer presented at ASCO 2024.

William Dale, MD, PhD, discusses the unmet needs of older patients requiring cancer treatment.

Holly Pederson, MD, and Elisha Hughes, PhD, discuss the findings and implications of a study evaluating risk of triple-negative breast cancer for Black women presented at the 2024 ASCO Annual Meeting.

Joseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advanced non-small cell lung cancer.

The combination therapy showed consistent benefits across various subgroups, including those with poor-risk disease and higher PD-L1 expression.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

Lynn Schuchter, MD, 2023-2024 ASCO president, discusses her top abstracts from the annual meeting.

A high complete response rate was achieved in patients with BCG–unresponsive NMIBC using the combination of cretostimogene grenadenorepvec and pembrolizumab, according to final phase 2 CORE-001 trial results.

Lenvatinib plus pembrolizumab delivered a significant benefit in time to disease progression in all organs vs sunitinib in advanced renal cell carcinoma.

Prophylactic treatment with tocilizumab shows promise for reducing a serious adverse effect in multiple myeloma treatment.

A promising new treatment option has emerged for patients with a specific type of gastrointestinal stromal tumor that has become resistant to standard therapy.

Frontline treatment with petosemtamab and pembrolizumab produced early clinical efficacy in patients with recurrent or metastatic head and neck squamous cell carcinoma.

The METIS trial of tumor treating fields for the treatment of brain metastases in patients with non–small cell lung cancer met its primary end point, showing a statistically significant improvement in time to intracranial progression.

The first safety run-in cohort of the MajesTEC-7 trial showed promising safety/efficacy results with teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma.

The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.

The combination of the adenovirus CAN-2409 and valacyclovir with continued immune checkpoint inhibitor therapy demonstrated favorable tolerability and induced a positive immune response.

A daratumumab-VRd–based regimen boosted the rate of MRD-negativity in patients with newly diagnosed, transplant-eligible multiple myeloma.

Tarah Ballinger, MD, discusses findings from the phase 2 EAZ171 study of taxane-induced peripheral neuropathy in Black patients with breast cancer.

In the HERCULES trial, pembrolizumab with platinum-based therapy showed promising safety and efficacy in the treatment of penile squamous cell carcinoma.

Treatment with ARV-766, an investigational proteolysis targeting chimera (PROTAC) androgen receptor degrader, led to a ≥50% PSA decline in 43% of patients with metastatic castration-resistant prostate cancer.

The IMROZ trial reveals significant improvements in PFS for patients with newly diagnosed, transplant-ineligible multiple myeloma.

A clinical complete response was observed in all 42 patients with locally advanced mismatch repair–deficient rectal cancer who completed treatment with the dostarlimab in a phase 2 study.

Perioperative nivolumab led to a significant improvement in event-free survival in the phase 3 CheckMate 77T trial in patients with stage III N2 and stage III non-N2 non–small cell lung cancer.

Datopotamab deruxtecan was efficacious among patients with non-small cell lung cancer and baseline brain metastases who harbor actionable genomic alterations, according to an exploratory analysis of the phase 2 TROPION-Lung05 trial.

Five-year follow-up from the IMpower010 trial shows atezolizumab improves overall survival vs BSC in resected stage IB-IIIA NSCLC.

A new radioligand therapy, JNJ-6420, shows promise in treating metastatic castration-resistant prostate cancer with deep and lasting responses after just 1-2 doses.